Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Super-strength antibiotic developed in California
Antibiotic pills
The developments could eradicate the threat of antibiotic-resistant infections for many years.

1,000-fold increase in activity of existing drug, vancomycin

Researchers at The Scripps Research Institute (TSRI) have structurally modified powerful antibiotic, vancomycin, to create a far stronger version of the drug.

The developments - led by Dale Boger and Akinori Okano, senior and first authors of the study at TSRI - could eradicate the threat of antibiotic-resistant infections for many years.

Vancomycin, an antibiotic that has been used for 60 years, presents a “mechanism of action” that bacteria have found difficult to overcome, up until now. This “mechanism” involves disrupting the process through which bacteria form cell walls, presenting a platform upon which new antibiotics can be developed.

In past studies, the team of TSRI scientists recognised the possibility of adding two modifications to vancomycin, to make it even more potent. Now, scientists have made a third modification that effects the bacterium cell wall in an additional way.

The three collective modifications give vancomycin a 1,000-fold amplification in activity, meaning less would be needed to treat infections. The modifications make vancomycin the first antibiotic to have three independent mechanisms of action.

Boger commented: “This increases the durability of this antibiotic. Organisms just can’t simultaneously work to find a way around three independent mechanisms of action. Even if they found a solution to one of those, the organisms would still be killed by the other two.”

When tested against Enterococci bacteria, the new version of vancomycin killed the resistant form of Enterococci, as well as the original forms of the bacteria. Scientists now need to develop a way to synthesise the new form of the antibiotic using a shorter laboratory process. The current method contains 30 different steps, however, Boger considers this the “easy part”, following the challenge of designing an effective molecule, in the first place.

Boger stated: “Antibiotics are total cures for bacterial infections. Making this molecule is important, even by the current approach, if the failure of antibiotics continues.”

Fellow authors, Akinori Okano and Nicholas A. Isley, said: “Peripheral modifications of vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.”

The breakthrough study was supported by the National Institutes of Health.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.